

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Avalglucosidase alfa for treating Pompe disease
[ID3737]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
<ul style="list-style-type: none">• Ensure no patient has to travel excessive distance to receive treatment given the level of disability that many will face <p>Issue relates to ease of access and will not vary between ALGLU and AVAL.</p> <ul style="list-style-type: none">• Consider BAME groups – possible that genetic, recessive condition has higher prevalence in communities with consanguineous marriage. This appears to be the case in both infantile and late-onset Pompe disease <p>Issue related to differences in prevalence or incidence of a disease that cannot be addressed in a technology appraisal.</p>
2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
None were raised

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
N/A

Approved by Associate Director (name):Janet Robertson...

Date: 24 August 2022

Technology appraisals: Guidance development

Equality impact assessment for the proposed Single Technology Appraisal of avalglucosidase alfa for treating Pompe disease [ID3737]

Issue date: August 2022